Category: Accuray Inc.
Accuray CEO Euan Thomson tells MassDevice about being a small fish in a big pond, managing growing pains and his strategies for breaking out in a well-established market.
When Euan Thomson landed in the corner office at radiosurgery device maker Accuray (NSDQ:ARAY) in 2002, the company was just preparing to penetrate a very well-established market.
Thoratec shares gain big today after the heart pump maker reports more than 46% profit growth for the 4th quarter, lifting full-year earnings growth above 34%; also, Accuray soars on Q2 results; Hanger's Q4, 2011 profits soar; Cerner posts double-digit increases for Q4, 2011; Steris posts solid Q3 growth; Misonix swings to Q2 black; Q2 losses double for Cardiovascular Systems; Q2 sales slump, losses gape for pSivida; and DermaGraft sales trickle in for Shire.
Thoratec (NSDQ:THOR) shares are up more than 11% today after the heart pump maker put mid-double-digit profit growth numbers on the board for the 4th quarter and full-year 2011.
The Pleasanton, Calif.-based cardiac assist device maker logged profits of $15.3 million, or 25 cents per diluted share, on sales of $109.4 million for the 3 months ended Dec. 31, 2011. That's a 46.4% bottom-line gain and a top-line boost of 12.1%, compared with profits of $10.5 million, or 17 cents diluted EPS, on sales of $97.6 million during Q4 2010.
The top seven medical device stories for the week of January 2, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.
The top three medical device stories for January 3, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Accuray amends a partnership to expand distribution rights for its newly acquired TomoTherapy's devices to Siemens.
Amid job losses and cost cutting measures, Accuray (NSDQ:ARAY) and Siemens AG (NYSE:SI) amended their strategic partnership to allow Siemens to sell CyberKnife products made by Accuray's recent acquisition, TomoTherapy Inc.
Accuray Inc. cuts 29 positions and plans to cut 22 more in order to reduce costs following its merger with TomoTherapy.
Accuray (NSDQ:ARAY) laid off 29 workers and plans to cut another 22 over the next three quarters, reducing its workforce by 5 percent.
The cancer treatment device maker aims to reduce costs following its $277 million acquisition of TomoTherapy Inc. (NSDQ:TOMO).
Accuray Inc.'s first-quarter results beat Wall Street's expectations, but investors still send its share price down 5 percent as the radiosurgery company's quarterly losses gape by more than 470 percent; also, results for CAS Medical Systems, Echo Therapeutics, CardioNet, Electromed, IntriCon, Bioject, Kips Bay Medical, Tornier, BioMimetic Therapeutics, Pro-Dex and Misonix.
Accuray (NSDQ:ARAY) shares are down today after the radiosurgery company reported surging first-quarter sales and beat Wall Street's earnings expectations, as investors reacted to net losses of nearly six times the Q1 2011 mark.
Accuray reported losses of $26.5 million, or 38 cents per share, on sales of $100.5 million for the three months ended Sept. 30. That's top-line growth of 163.9 percent compared with the same period last year, largely due to the massive infusion that followed ARAY's acquisition of rival TomoTherapy earlier this year.